On Monday, we highlighted opportunity in Second Sight Medical (EYES).
After running from about $9 to $12 yesterday, the stock is up to $20.62 this morning. All on news the FDA approved its Argus 2s Retinal Prosthesis System.
According to the company, the System is, “a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company expects that the Argus 2s will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System currently under development.”
From here, we’d like to see EYES test $25 a share.
In addition, according to The Street, “RP is a rare genetic disorder that involves the breakdown and loss of cells in the retina of the eye. It causes vision loss that worsens over time and can eventually lead to blindness. Second Sight’s Argus 2s is a set of external hardware, glasses and a video processing unit that assists in offsetting the effects of the condition.”
